Lipoprotein(a) and Stroke

Presented by

Larry Goldstein, MD, FAAN, FANA, FAHA

Judy and Byron Young Neuroscience Institute Endowed Professor

Chair, Department of Neurology

Neurologist-in-Chief, UK HealthCare

Co-Director, Kentucky Neuroscience Institute

Medical Director, UK-Norton Healthcare Stroke Care Network

University of Kentucky

Hend Abdelhamid, MBBCh

PGY3 Resident in Neurology

University of Kentucky

Tuesday, October 27, 2026

8:00 – 9:00 AM EDT

Zoom only: https://uky.zoom.us/j/81485627103

After this session, participants will be able to:

• Describe Lp(a) structure and genetics
• Explain mechanisms linking Lp(a) to ischemic stroke
• Review epidemiologic and Mendelian randomization evidence
• Identify populations for Lp(a) testing
• Discuss current and emerging therapeutic approaches

   

  Disclosure of Financial Interest Summary

  All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

  Larry Goldstein, MD, FAAN, FANA, FAHA, faculty for this educational event, is a Co-Chair for the International Data Safety Monitoring Board for a clinical trial sponsored by Janssen.

  All of the relevant financial relationships listed for this individual have been mitigated.

  The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include a discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

  Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.